Modification and Validation of the Phosphate Removal Model: A Multicenter Study
Kidney & Blood Pressure Research, 2021 Background: Our research group has previously reported a noninvasive model that estimates phosphate removal within a 4-h hemodialysis (HD) treatment. The aim of this study was to modify the original model and validate the accuracy of the new model of ...
Weichen Zhang +7 more
doaj +1 more source
Npt2a as a target for treating hyperphosphatemia [PDF]
Biochemical Society Transactions, 2022 Hyperphosphatemia results from an imbalance in phosphate (Pi) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral Pi binder and dietary Pi restriction.
Linto Thomas +2 more
openaire +2 more sources
An Unusual Combination of Neurological Manifestations and Sudden Vision Loss in a Child with Familial Hyperphosphatemic Tumoral Calcinosis [PDF]
, 2019 Hyperphosphatemia in the absence of renal failure is an unusual occurrence, particularly in children, but is a common primary feature of familial hyperphosphatemic tumor calcinosis.
Acton, Dena +7 more
core +1 more source
Renal Failure, 2022 Background Hyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC),
Li Li +5 more
doaj +1 more source
Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm.
Journal of renal nutrition, 2020 Bone and mineral metabolism becomes dysregulated with progression of chronic kidney disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive response to maintain normal phosphorus and calcium levels.
A. Rastogi +3 more
semanticscholar +1 more source
Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies [PDF]
, 2018 Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal recessive disorder of ectopic calcification due to deficiency of or resistance to intact fibroblast growth factor 23 (iFGF23). Inactivating
Burbelo +14 more
core +1 more source
Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability. [PDF]
PLoS ONE, 2011 Dysregulation of phosphate homeostasis as occurs in chronic kidney disease is associated with cardiovascular complications. It has been suggested that both hyperphosphatemia and hypophosphatemia can cause cardiovascular disease.
Ai Peng +10 more
doaj +1 more source
Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia
Cellular and Molecular Life Sciences, 2019 Medial vascular calcification has emerged as a putative key factor contributing to the excessive cardiovascular mortality of patients with chronic kidney disease (CKD).
J. Voelkl +7 more
semanticscholar +1 more source
eLife, 2022 Elevations in plasma phosphate concentrations (hyperphosphatemia) occur in chronic kidney disease (CKD), in certain genetic disorders, and following the intake of a phosphate-rich diet.
Brian Czaya +11 more
doaj +1 more source
Effects of education on low-phosphate diet and phosphate binder intake to control serum phosphate among maintenance hemodialysis patients: A randomized controlled trial. [PDF]
, 2018 Background:For phosphate control, patient education is essential due to the limited clearance of phosphate by dialysis. However, well-designed randomized controlled trials about dietary and phosphate binder education have been scarce. Methods:We enrolled
Hyun, Sunah +11 more
core +2 more sources